SCHEDULE 13G/A: Madison Avenue Entities Maintain 4% Passive Stake in Ovid Therapeutics

A group of investment entities, including Madison Avenue Partners, LP and Madison Avenue International LP, have disclosed an updated passive 4% beneficial ownership stake in Ovid Therapeutics Inc., holding 2,852,352 shares as of December 31, 2024.

Summary

• The filing is an Amendment No. 2 to a Schedule 13G, disclosing beneficial ownership of Ovid Therapeutics Inc. Common Stock.
• The reporting persons include Madison Avenue Partners, LP, Madison Avenue International LP, EMAI Management, LLC, Madison Avenue GP, LLC, Caraway Jackson Investments LLC, and Eli Samaha.
• As of December 31, 2024, the reporting persons collectively beneficially owned 2,852,352 shares of Ovid Therapeutics Inc. Common Stock.
• This ownership represents approximately 4.0% of the outstanding shares of Common Stock.
• The percentage is based on 71,009,866 shares of Common Stock outstanding as of November 8, 2024, as disclosed in Ovid Therapeutics Inc.'s Quarterly Report on Form 10-Q.
• The reporting persons hold shared voting power and shared dispositive power over all 2,852,352 shares.
• The securities were acquired and are held for passive investment purposes and not with the intent to change or influence the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the issuer's performance or prospects.

Positives

• A group of investment entities continues to hold a significant 4% passive stake in Ovid Therapeutics Inc., indicating continued confidence in the company's long-term value by these investors.

Negatives

• The document does not contain information regarding negative operational or financial performance of Ovid Therapeutics Inc.

Risks

• The disclosed ownership is passive, meaning the reporting persons do not intend to influence or change the control of Ovid Therapeutics Inc., which limits potential for activist shareholder engagement.

Future Outlook

This document, a Schedule 13G, is a beneficial ownership disclosure and does not contain forward-looking statements or guidance from Ovid Therapeutics Inc. regarding its future outlook.

Industry Context

This Schedule 13G filing primarily concerns beneficial ownership disclosure and does not provide specific analysis of broader industry trends or Ovid Therapeutics Inc.'s competitive position within its industry.

Comparison to Industry Standards

• This document is a beneficial ownership filing and does not contain information suitable for comparison to industry standards, specific comparable companies, projects, or results.

Stakeholder Impact

• This filing primarily impacts shareholders by disclosing a significant passive ownership stake, which may be viewed as a vote of confidence by the reporting entities. It does not directly impact employees, customers, suppliers, or creditors.

Next Steps

• The document does not specify any future actions, events, or milestones for Ovid Therapeutics Inc.

Key Dates

Keywords

Ovid Therapeutics, Schedule 13G, Beneficial Ownership, Passive Investment, Madison Avenue Partners, Madison Avenue International, SEC Filing, Common Stock